ATNM
Income statement / Annual
Last year (2024), Actinium Pharmaceuticals, Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2024, Actinium Pharmaceuticals, Inc.'s net income was -$38.24 M.
See Actinium Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$81.00 K |
$1.03 M |
$1.14 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$790.00 K
|
$699.00 K
|
$524.00 K
|
$447.00 K
|
$420.09 K
|
$50.72 K
|
$55.94 K
|
$77.52 K
|
$0.00
|
| Gross Profit |
$0.00
|
$81.00 K
|
$331.00 K
|
$620.00 K
|
-$447.00 K
|
-$420.00 K
|
-$50.72 K
|
-$55.94 K
|
-$77.52 K
|
-$53.47 K
|
| Gross Profit Ratio |
0
|
1
|
0.32
|
0.54
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$30.05 M
|
$38.67 M
|
$23.14 M
|
$18.03 M
|
$16.09 M
|
$16.55 M
|
$17.10 M
|
$17.70 M
|
$17.50 M
|
$13.31 M
|
| General & Administrative Expenses |
$12.08 M
|
$13.33 M
|
$12.00 M
|
$8.08 M
|
$6.31 M
|
$5.52 M
|
$6.73 M
|
$9.16 M
|
$9.27 M
|
$11.47 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$12.08 M
|
$13.33 M
|
$12.00 M
|
$8.08 M
|
$6.31 M
|
$5.52 M
|
$6.73 M
|
$9.16 M
|
$9.27 M
|
$11.47 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$55.94 K
|
$77.52 K
|
$53.47 K
|
| Operating Expenses |
$42.12 M
|
$52.00 M
|
$35.13 M
|
$26.11 M
|
$22.39 M
|
$22.07 M
|
$23.83 M
|
$26.91 M
|
$26.85 M
|
$24.83 M
|
| Cost And Expenses |
$0.00
|
$52.00 M
|
$35.13 M
|
$26.11 M
|
$22.39 M
|
$22.07 M
|
$23.83 M
|
$26.91 M
|
$26.85 M
|
$24.83 M
|
| Interest Income |
$0.00
|
$3.10 M
|
$1.09 M
|
$190.00 K
|
$178.00 K
|
$172.39 K
|
$173.36 K
|
$5.43 K
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$173.36 K
|
$5.43 K
|
$5.01 K
|
$7.87 K
|
| Depreciation & Amortization |
$811.00 K
|
$790.00 K
|
$699.00 K
|
$524.00 K
|
$447.00 K
|
$420.09 K
|
$50.72 K
|
$55.94 K
|
$77.52 K
|
$53.47 K
|
| EBITDA |
-$37.43 M |
-$51.13 M |
-$33.41 M |
-$24.44 M |
-$21.77 M |
-$21.48 M |
-$23.78 M |
-$26.86 M |
-$26.77 M |
-$24.78 M |
| EBITDA Ratio |
0
|
-631.23
|
-32.43
|
-21.36
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
-640.99
|
-33.11
|
-21.82
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$3.88 M
|
$3.10 M
|
$1.09 M
|
$190.00 K
|
$178.00 K
|
$172.39 K
|
$173.36 K
|
$309.55 K
|
$2.53 M
|
$3.80 M
|
| Income Before Tax |
-$38.24 M
|
-$48.82 M
|
-$33.02 M
|
-$24.77 M
|
-$22.22 M
|
-$21.90 M
|
-$23.65 M
|
-$26.60 M
|
-$24.32 M
|
-$21.03 M
|
| Income Before Tax Ratio |
0
|
-602.69
|
-32.06
|
-21.66
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
-$190.00 K
|
-$178.00 K
|
-$172.00 K
|
$173.36 K
|
$0.00
|
$5.01 K
|
$7.87 K
|
| Net Income |
-$38.24 M
|
-$48.82 M
|
-$33.02 M
|
-$24.58 M
|
-$22.04 M
|
-$21.73 M
|
-$23.65 M
|
-$26.60 M
|
-$24.32 M
|
-$21.03 M
|
| Net Income Ratio |
0
|
-602.69
|
-32.06
|
-21.49
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1.27 |
-1.83 |
-1.37 |
-1.2 |
-1.82 |
-4.37 |
-6.69 |
-11.96 |
-15.06 |
-16.53 |
| EPS Diluted |
-1.27 |
-1.83 |
-1.37 |
-1.2 |
-1.82 |
-4.37 |
-6.69 |
-11.96 |
-15.06 |
-16.53 |
| Weighted Average Shares Out |
$30.07 M
|
$26.60 M
|
$24.14 M
|
$20.57 M
|
$12.13 M
|
$4.98 M
|
$3.54 M
|
$2.23 M
|
$1.62 M
|
$1.27 M
|
| Weighted Average Shares Out Diluted |
$30.07 M
|
$26.60 M
|
$24.14 M
|
$20.57 M
|
$12.13 M
|
$4.98 M
|
$3.54 M
|
$2.23 M
|
$1.62 M
|
$1.27 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
